US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Direxion NVDA Defined Income Boost ETF

29.14

+0.43071.50%

Post-market: 29.170.0298+0.10%16:10 EDT

Volume:1K

Turnover:29.61K

Market Cap:2.62M

PE:- -

High:29.31

Open:29.30

Low:29.14

Close:28.71

52wk High:29.31

52wk Low:24.54

Shares:90.00K

Float Shares:90.00K

Volume Ratio:1.28

T/O Rate:1.12%

Dividend:0.92

Dividend Rate:3.15%

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026

DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years

Liver safety concerns emerge for Bristol Myers’ admilparant, says Wells Fargo

New Grades, Price Targets for the Top-3 Stocks in the Market’s Hottest Sector

NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease

Invivyd Phase 3 COVID Antibody Trial Shows Superior Safety

CSPC Launches Phase Ib Trial of Obesity Biologic JMT206 in China

Teva announces FDA approval of Degevma as a biosimilar to Xgeva

Transcode Therapeutics reports updated results from Phase 1a TTX-MC138 trial

Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD

4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME

U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations

Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate

Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine

MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001

Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M

Hutchmed initiates Phase Ia part of trial of HMPL-A830

EBR Systems advances FDA approval process for new WiSE manufacturing site

GT Biopharma Regains Nasdaq Minimum Bid Compliance

Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://hk.tigershowtime.com/stock/NVIB/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"NVIB","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","market":"US","secType":"STK","nameCN":"Direxion NVDA Defined Income Boost ETF","latestPrice":29.1392,"timestamp":1790971200000,"preClose":28.7085,"halted":0,"volume":1011,"hourTrading":{"tag":"盘后","latestPrice":29.169,"preClose":29.1392,"latestTime":"16:10 EDT","volume":6,"amount":174.8352,"timestamp":1790971804945,"change":0.0298,"changeRate":0.001023,"amplitude":0},"delay":0,"changeRate":0.015002525384467948,"floatShares":90001,"shares":90001,"eps":0,"marketStatus":"Market Closed","change":0.4307,"latestTime":"10-02 16:00:00 EDT","open":29.3,"high":29.31,"low":29.1392,"amount":29609,"amplitude":0.005949,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1791187200000},"marketStatusCode":7,"adr":0,"listingDate":1785297600000,"exchange":"CBOE","adjPreClose":28.7085,"nav":29.11,"aum":2619962.27,"dividendRate":0.031511,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":29.169,"preClose":29.1392,"latestTime":"16:10 EDT","volume":6,"amount":174.8352,"timestamp":1790971804945,"change":0.0298,"changeRate":0.001023,"amplitude":0},"volumeRatio":1.282669145427962},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NVIB\",,,,,undefined,":{"symbol":"NVIB","floatShares":90001,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.282669145427962,"shares":90001,"dividePrice":0.9182,"high":29.31,"amplitude":0.005949,"preClose":28.7085,"low":29.1392,"week52Low":24.54,"pbRate":"--","week52High":29.31,"institutionHeld":0,"latestPrice":29.1392,"eps":0,"divideRate":0.031511,"volume":1011,"delay":0,"ttmEps":0,"open":29.3,"prevYearClose":25,"prevWeekClose":28.0966,"prevMonthClose":28.4278,"prevQuarterClose":28.4278,"fiveDayClose":28.0966,"twentyDayClose":28.4889},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NVIB\",params:#limit:5,,,undefined,":[{"date":"2026-09-30","symbol":"NVIB","amount":0.23782,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-30","defaultRemindTime":1790775000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-10-01","payableDate":"2026-09-30","currency":"USD","dateTimestamp":1790740800000,"payDate":"2026-10-01"},{"date":"2026-09-15","symbol":"NVIB","amount":0.22766,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-09-15","defaultRemindTime":1789479000000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-09-16","payableDate":"2026-09-15","currency":"USD","dateTimestamp":1789444800000,"payDate":"2026-09-16"},{"date":"2026-08-28","symbol":"NVIB","amount":0.21733,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-28","defaultRemindTime":1787923800000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-31","payableDate":"2026-08-28","currency":"USD","dateTimestamp":1787889600000,"payDate":"2026-08-31"},{"date":"2026-08-14","symbol":"NVIB","amount":0.23454,"announcedDate":"2026-08-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2026-08-14","defaultRemindTime":1786714200000,"name":"Direxion NVDA Defined Income Boost ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2026-08-17","payableDate":"2026-08-14","currency":"USD","dateTimestamp":1786680000000,"payDate":"2026-08-17"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NVIB\",market:\"US\",,,undefined,":[{"executeDate":"2026-08-14","recordDate":"2026-08-14","paymentDate":"2026-08-17","value":0.23454,"currency":"USD"},{"executeDate":"2026-08-28","recordDate":"2026-08-28","paymentDate":"2026-08-31","value":0.21733,"currency":"USD"},{"executeDate":"2026-09-15","recordDate":"2026-09-15","paymentDate":"2026-09-16","value":0.22766,"currency":"USD"},{"executeDate":"2026-09-30","recordDate":"2026-09-30","paymentDate":"2026-10-01","value":0.23782,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NVIB\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NVIB\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671087702","title":"Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2671087702","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671087702?lang=en_us&edition=fundamental","pubTime":"2026-09-30 18:00","pubTimestamp":1790762400,"startTime":"0","endTime":"0","summary":"In the Phase 3 open-label extension clinical trial (OLE), patients with moderate to severe acne received denifanstat for up to 52 weeks, including prior placebo patientsDenifanstat showed progressive ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/30/3371663/0/en/sagimet-announces-positive-full-52-week-results-from-license-partner-ascletis-phase-3-open-label-extension-clinical-trial-of-denifanstat-in-acne-presented-at-eadv-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SD","IDNA","HYLG","GDOC","NVIB","IGA","MEDX","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671942228","title":"DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years","url":"https://stock-news.laohu8.com/highlight/detail?id=2671942228","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671942228?lang=en_us&edition=fundamental","pubTime":"2026-09-30 06:29","pubTimestamp":1790720940,"startTime":"0","endTime":"0","summary":"Chtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for theVIASKIN Peanut Patch in Children Aged 4-7 Years  TheBLAis supportedbyther","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/29/3371452/0/en/dbv-technologies-announces-submission-of-biologics-license-application-to-u-s-fda-for-the-viaskin-peanut-patch-in-children-aged-4-7-years.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","BK4588","HYLG","NVIB","MEDX","BK4585","LABU","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671054242","title":"Liver safety concerns emerge for Bristol Myers’ admilparant, says Wells Fargo","url":"https://stock-news.laohu8.com/highlight/detail?id=2671054242","media":"TIPRANKS","labels":["policyRegulatory","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671054242?lang=en_us&edition=fundamental","pubTime":"2026-09-30 04:10","pubTimestamp":1790712632,"startTime":"0","endTime":"0","summary":"Wells Fargo says admilparant protocol documents on EU clinical trials suggest liver safety issues in blinded Phase 3 data. While the firm says “we ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/liver-safety-concerns-emerge-for-bristol-myers-admilparant-says-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/liver-safety-concerns-emerge-for-bristol-myers-admilparant-says-wells-fargo-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory,merge","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","IE00B19Z3581.USD","HYLG","LU0310799852.SGD","LU1668664300.SGD","BK4585","MYE","KBWB","PGF","BK4559","IE000M9KFDE8.USD","LU1791807156.HKD","LU1894683348.USD","BMED","IE00B7SZLL34.SGD","LU2361045086.USD","LU0320765489.SGD","LU1894683264.USD","BK4504","LU1506573853.SGD","LU0048573561.USD","LU1280957306.USD","BK4126","LU0154236417.USD","LU0251131958.USD","IE00B19Z3B42.SGD","LU0175139822.USD","LU0211327993.USD","LU0267386448.USD","LU0942090050.USD","LU0289960550.SGD","BK4588","LU0980610538.SGD","FTXO","NVIB","LU0310800379.SGD","BK4582","LU0162691827.USD","LU0211328371.USD","LU0052756011.USD","LU0029864427.USD","LU1363072403.SGD","LU1074936037.SGD","LU0971096721.USD","TFNS","IYF","LU2236285917.USD","MEDX","LU1035773651.USD","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671117244","title":"New Grades, Price Targets for the Top-3 Stocks in the Market’s Hottest Sector","url":"https://stock-news.laohu8.com/highlight/detail?id=2671117244","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671117244?lang=en_us&edition=fundamental","pubTime":"2026-09-30 02:43","pubTimestamp":1790707417,"startTime":"0","endTime":"0","summary":"How hot are biotech stocks? One of the bellwethers for the industry, the iShares Biotechnology ETF ($IBB) (left chart), has gained over 24% year to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/new-grades-price-targets-for-the-top-3-stocks-in-the-markets-hottest-sector?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/new-grades-price-targets-for-the-top-3-stocks-in-the-markets-hottest-sector?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4588","IBB","PTH","FDN","BK4550","BIS","JHMH","NVIB","XLK","RXL","FBT","BIOY","XBIX","FXH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671949211","title":"NewAmsterdam Pharma Doses First Participant in Phase 2b SPINOZA Trial Evaluating Obicetrapib in Preclinical Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2671949211","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671949211?lang=en_us&edition=fundamental","pubTime":"2026-09-29 20:00","pubTimestamp":1790683200,"startTime":"0","endTime":"0","summary":"- SPINOZA is studying obicetrapib in adults with biomarker evidence suggestive of preclinical Alzheimer’s disease who do not have noticeable memory or functional symptoms- - The study will evaluate ch","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/29/3370754/0/en/newamsterdam-pharma-doses-first-participant-in-phase-2b-spinoza-trial-evaluating-obicetrapib-in-preclinical-alzheimer-s-disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","BK4080","NVIB","CDR","BMED","HYLG","GDOC","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671116862","title":"Invivyd Phase 3 COVID Antibody Trial Shows Superior Safety","url":"https://stock-news.laohu8.com/highlight/detail?id=2671116862","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671116862?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:49","pubTimestamp":1790682559,"startTime":"0","endTime":"0","summary":"The latest update is out from Invivyd ( ($IVVD) ). Invivyd, Inc. is a clinical-stage biotech company developing antiviral monoclonal antibodies, le...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/invivyd-phase-3-covid-antibody-trial-shows-superior-safety?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/invivyd-phase-3-covid-antibody-trial-shows-superior-safety?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BBC","XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671213179","title":"CSPC Launches Phase Ib Trial of Obesity Biologic JMT206 in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2671213179","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671213179?lang=en_us&edition=fundamental","pubTime":"2026-09-29 18:07","pubTimestamp":1790676452,"startTime":"0","endTime":"0","summary":"CSPC Pharmaceutical Group ( ($HK:1093) ) has shared an update. CSPC Pharmaceutical Group has initiated a Phase Ib clinical trial in China for JMT20...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/cspc-launches-phase-ib-trial-of-obesity-biologic-jmt206-in-china?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/cspc-launches-phase-ib-trial-of-obesity-biologic-jmt206-in-china?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","NVIB","MEDX","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671125702","title":"Teva announces FDA approval of Degevma as a biosimilar to Xgeva","url":"https://stock-news.laohu8.com/highlight/detail?id=2671125702","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671125702?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:05","pubTimestamp":1790625914,"startTime":"0","endTime":"0","summary":"Teva (TEVA) Pharmaceutical Industries announced that the FDA has approved Degevma as a biosimilar to Xgeva. Degevma is indicated for the prevention...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/teva-announces-fda-approval-of-degevma-as-a-biosimilar-to-xgeva-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IYH","TBXU","BK4596","IEIH","BK4559","MRNY","BK4584","LU2324357040.USD","TEVA","PINK","GDOC","BK4585","XLVX","BK4588","BK4566","SYNB","NVIB","RSPH","BBP","LFSC","LABU","BK4557","BK4007","MRNX","BMED","TECB","FRTY","LU1983299246.USD","MEDI","IBB","IDNA","PSCH","GNMX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670204232","title":"Transcode Therapeutics reports updated results from Phase 1a TTX-MC138 trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2670204232","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670204232?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:10","pubTimestamp":1790597436,"startTime":"0","endTime":"0","summary":"TransCode Therapeutics (RNAZ) announced updated clinical data from its Phase 1a clinical trial of TTX-MC138, its novel anti-miR-10b therapeutic can...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/transcode-therapeutics-reports-updated-results-from-phase-1a-ttx-mc138-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/transcode-therapeutics-reports-updated-results-from-phase-1a-ttx-mc138-trial-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GDOC","NVIB","RNAZ","MEDX","HYLG","IDNA","LENZ","BK4007","BK4539","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670523240","title":"Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD","url":"https://stock-news.laohu8.com/highlight/detail?id=2670523240","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670523240?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:00","pubTimestamp":1790596800,"startTime":"0","endTime":"0","summary":"Initial data expected in the first half of 2027LEXINGTON, Mass., Sept.  28, 2026 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focus","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369820/0/en/keros-therapeutics-announces-the-first-patient-dosing-in-the-phase-2-clinical-trial-evaluating-rinvatercept-in-dmd.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HYLG","BK4539","LENZ","NVIB","BK4007","IDNA","GDOC","BK4139","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670324162","title":"4DMT Advances 4D-150 into Phase 3 for Second Large Market Retina Indication with Initiation of 4SIGHT in DME","url":"https://stock-news.laohu8.com/highlight/detail?id=2670324162","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670324162?lang=en_us&edition=fundamental","pubTime":"2026-09-28 20:00","pubTimestamp":1790596800,"startTime":"0","endTime":"0","summary":"4D-150 is advancing into Phase 3 development for DME, a second multi-billion-dollar retinal disease market with significant unmet needFirst patients have been enrolled in 4SIGHT global Phase 3 trial (","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369825/0/en/4dmt-advances-4d-150-into-phase-3-for-second-large-market-retina-indication-with-initiation-of-4sight-in-dme.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CNAV","CST","WUGI","TEK","AMDW","BK4534","IE00BMPRXN33.USD","TRFK","ARTY","IETC","CHAT","TTEQ","BAI","AMDD","AMDL","AMDU","LU2108987350.USD","LU0979878070.USD","AMDC","AMDG","AMUU","GDOC","NVIB","LU1852331112.SGD","MEDX","FAI","XNTK","AMYY","AMDY","GAMR","SOXX","SOXY","FTXL","SAMD0main","USXF","DAMD","AIQ","AMD","HYLG","CHPS","QQQA","WISE","IDNA","SMH","AIS","AMDS","SMHX","ILDR","LEGR","PSI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670234567","title":"U.S. Food and Drug Administration Awards Additional Funding for QTORIN™ Rapamycin for the Treatment of Microcystic Lymphatic Malformations","url":"https://stock-news.laohu8.com/highlight/detail?id=2670234567","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670234567?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:30","pubTimestamp":1790595000,"startTime":"0","endTime":"0","summary":"NDA submission completed following positive Phase 3 SELVA results; potential U.S. commercial launch in the first half of 2027, if approved QTORIN rapamycin has the potential to become the first FDA-ap","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369784/0/en/u-s-food-and-drug-administration-awards-additional-funding-for-qtorin-rapamycin-for-the-treatment-of-microcystic-lymphatic-malformations.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MEDX","LABU","BMED","HYLG","BK4585","GDOC","IDNA","BK4588","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670313732","title":"Arvinas Announces First Patient Dosed in Phase 1/2 Clinical Trial of ARV-6723, the Company’s First Immuno-Oncology Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2670313732","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670313732?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:00","pubTimestamp":1790593200,"startTime":"0","endTime":"0","summary":"– ARV-6723 is an investigational, oral PROTAC designed to degrade HPK1, a negative regulator of immune activation, in advanced solid tumors – NEW HAVEN, Conn., Sept.  28, 2026 (GLOBE NEWSWIRE) -- Arvi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369737/0/en/arvinas-announces-first-patient-dosed-in-phase-1-2-clinical-trial-of-arv-6723-the-company-s-first-immuno-oncology-candidate.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GDOC","NVIB","MEDX","HYLG","IDNA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670313352","title":"Moleculin Announces Publication of Peer-Reviewed Cardiac Safety Analysis of Annamycin in Frontiers in Cardiovascular Medicine","url":"https://stock-news.laohu8.com/highlight/detail?id=2670313352","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670313352?lang=en_us&edition=fundamental","pubTime":"2026-09-28 19:00","pubTimestamp":1790593200,"startTime":"0","endTime":"0","summary":"–Pooled analysis of five clinical trials found no clinical or subclinical evidence of cardiotoxicity at cumulative doses exceeding traditional anthracycline limits –Independent Cleveland Clinic cardio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/28/3369741/0/en/moleculin-announces-publication-of-peer-reviewed-cardiac-safety-analysis-of-annamycin-in-frontiers-in-cardiovascular-medicine.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IDNA","GDOC","NVIB","CSII","HYLG","BMED","MEDX","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670605236","title":"MediciNova reports results from MN-001-NATG-202 Phase 2 trial of MN-001","url":"https://stock-news.laohu8.com/highlight/detail?id=2670605236","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670605236?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:15","pubTimestamp":1790590507,"startTime":"0","endTime":"0","summary":"MediciNova (MNOV) announced the topline results from MN-001-NATG-202, a Phase 2 clinical trial evaluating MN-001 for the treatment of hypertriglyce...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/medicinova-reports-results-from-mn-001-natg-202-phase-2-trial-of-mn-001-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/medicinova-reports-results-from-mn-001-natg-202-phase-2-trial-of-mn-001-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IDNA","MNOV","GDOC","HYLG","PSIL","NVIB","MEDX","BBC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670236928","title":"Zymeworks sees FY26 revenue $278M-$292M, consensus $304.04M","url":"https://stock-news.laohu8.com/highlight/detail?id=2670236928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670236928?lang=en_us&edition=fundamental","pubTime":"2026-09-28 18:10","pubTimestamp":1790590220,"startTime":"0","endTime":"0","summary":"With the completion of the Theravance Biopharma acquisition and the receipt of the U.S. FDA approval of Ziihera for first-line HER2-positive advanc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/zymeworks-sees-fy26-revenue-278m-292m-consensus-304-04m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["TBPH","BMED","MRNX","TECB","MEDI","GDOC","GNMX","LABU","LFSC","IYH","MRNY","BK4007","BK4588","NVIB","FRTY","IDNA","XLVX","BBP","PSCH","IEIH","SYNB","RSPH","PINK","IBB","BK4585","TBXU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670402037","title":"Hutchmed initiates Phase Ia part of trial of HMPL-A830","url":"https://stock-news.laohu8.com/highlight/detail?id=2670402037","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670402037?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:45","pubTimestamp":1790556321,"startTime":"0","endTime":"0","summary":"Hutchmed (HCM) announces that it has initiated the Phase Ia part of a global clinical trial of HMPL-A830 in patients with unresectable, advanced or...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hutchmed-initiates-phase-ia-part-of-trial-of-hmpl-a830-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hutchmed-initiates-phase-ia-part-of-trial-of-hmpl-a830-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","HCM","BK4007","IDNA","MEDX","NVIB","BK4531","HYLG","BK4585","GDOC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670402990","title":"EBR Systems advances FDA approval process for new WiSE manufacturing site","url":"https://stock-news.laohu8.com/highlight/detail?id=2670402990","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670402990?lang=en_us&edition=fundamental","pubTime":"2026-09-28 08:08","pubTimestamp":1790554084,"startTime":"0","endTime":"0","summary":"The latest announcement is out from EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh ( ($AU:EBR) ). EBR Systems, developer of the WiSE wi...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ebr-systems-advances-fda-approval-process-for-new-wise-manufacturing-site?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MEDI","EES","PSCH","FRTY","GDOC","IDNA","MRNX","BMED","IYH","XLVX","BK4588","LABU","BBP","TECB","GNMX","TBXU","SYNB","NVIB","IBB","LFSC","IEIH","BK4585","MRNY","RSPH","PINK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670553422","title":"GT Biopharma Regains Nasdaq Minimum Bid Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=2670553422","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670553422?lang=en_us&edition=fundamental","pubTime":"2026-09-26 04:54","pubTimestamp":1790369640,"startTime":"0","endTime":"0","summary":"GT Biopharma ( ($GTBP) ) has provided an announcement. GT Biopharma, Inc., a Nasdaq-listed biotech company, had fallen out of compliance with the e...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/gt-biopharma-regains-nasdaq-minimum-bid-compliance?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/gt-biopharma-regains-nasdaq-minimum-bid-compliance?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XBIX","GT","LCLG","BK4588","NQmain","BK4119","BK4585","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669934134","title":"Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR","url":"https://stock-news.laohu8.com/highlight/detail?id=2669934134","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669934134?lang=en_us&edition=fundamental","pubTime":"2026-09-24 20:00","pubTimestamp":1790251200,"startTime":"0","endTime":"0","summary":"Montreal Heart Institute Joins Multinational Study Evaluating a Self-Administered 70 mg Repeat-Dose Regimen of EtripamilMONTREAL and CHARLOTTE, N.C., Sept.  24, 2026 (GLOBE NEWSWIRE) -- Milestone Phar","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/24/3368250/0/en/milestone-pharmaceuticals-enrolls-first-canadian-study-participant-in-revera-301-phase-3-pivotal-trial-evaluating-etripamil-nasal-spray-for-afib-rvr.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","VR","IDNA","BK4129","MEDX","BK4585","LU1559883803.SGD","NVIB","LU0566484027.USD","GDOC","HYLG","AV","ECG","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":2,"totalSize":200,"code":"91000000","status":"200"}]}}